GLP-1 clinical studies

Published trials by medicine, population and endpoint, with results and original sources.

Clinical trial results at a glance

Phase 3b · 72 weeks

Wegovy injection

Mean body weight change

Phase 3b · 72 weeks

MounjaroWegovy injection

Mean body weight change

Phase 3b · 64 weeks

Wegovy tablets

Mean body weight change

4 of 19 studies

Search trialsMedicineOutcome

Study	Medicine	Population & follow-up	Published results	Source
ATTAIN-JPhase 3 · 2026 · 238 participants FoundayoJapan · mixed diabetes status · 72 weeks	Foundayo	Japan · mixed diabetes status72 weeks	Mean body weight change at 72 weeks Orforglipron 6 mg −5.9% Orforglipron 12 mg −8.7% Orforglipron 36 mg −7.9% Placebo −0.6%	Paper
ATTAIN-MAINTAINPhase 3b · 2026 · 376 participants FoundayoAfter injectable treatment · 52 weeks	Foundayo	After injectable treatment52 weeks	Estimated share of earlier weight loss maintained at week 52 among participants who had reached a weight plateau Orforglipron after tirzepatide 74.7% Placebo after tirzepatide 49.2% Orforglipron after semaglutide 79.3% Placebo after semaglutide 37.6%	Paper
ATTAIN-1Phase 3 · 2025 · 3,127 participants FoundayoWithout diabetes · 72 weeks	Foundayo	Without diabetes72 weeks	Mean body weight change at 72 weeks Orforglipron 6 mg −7.5% Orforglipron 12 mg −8.4% Orforglipron 36 mg −11.2% Placebo −2.1%	Paper
ATTAIN-2Phase 3 · 2025 · 1,613 participants FoundayoWith type 2 diabetes · 72 weeks	Foundayo	With type 2 diabetes72 weeks	Mean body weight change at 72 weeks Orforglipron 6 mg −5.1% Orforglipron 12 mg −7.0% Orforglipron 36 mg −9.6% Placebo −2.5%	Paper

Open a study to see doses, comparators and the exact endpoint.